Skullcapflavone II, a novel NQO1 inhibitor, alleviates aristolochic acid I-induced liver and kidney injury in mice
Open Access
- 25 January 2023
- journal article
- research article
- Published by Springer Nature in Acta Pharmacologica Sinica
- Vol. 44 (7) , 1429-1441
Abstract
Aristolochic acid I (AAI) is a well established nephrotoxin and human carcinogen. Cytosolic NAD(P)H quinone oxidoreductase 1 (NQO1) plays an important role in the nitro reduction of aristolochic acids, leading to production of aristoloactam and AA-DNA adduct. Application of a potent NQO1 inhibitor dicoumarol is limited by its life-threatening side effect as an anticoagulant and the subsequent hemorrhagic complications. As traditional medicines containing AAI remain available in the market, novel NQO1 inhibitors are urgently needed to attenuate the toxicity of AAI exposure. In this study, we employed comprehensive 2D NQO1 biochromatography to screen candidate compounds that could bind with NQO1 protein. Four compounds, i.e., skullcapflavone II (SFII), oroxylin A, wogonin and tectochrysin were screened out from Scutellaria baicalensis. Among them, SFII was the most promising NQO1 inhibitor with a binding affinity (KD = 4.198 μmol/L) and inhibitory activity (IC50 = 2.87 μmol/L). In human normal liver cell line (L02) and human renal proximal tubular epithelial cell line (HK-2), SFII significantly alleviated AAI-induced DNA damage and apoptosis. In adult mice, oral administration of SFII dose-dependently ameliorated AAI-induced renal fibrosis and dysfunction. In infant mice, oral administration of SFII suppressed AAI-induced hepatocellular carcinoma initiation. Moreover, administration of SFII did not affect the coagulation function in short term in adult mice. In conclusion, SFII has been identified as a novel NQO1 inhibitor that might impede the risk of AAI to kidney and liver without obvious side effect.Keywords
This publication has 56 references indexed in Scilit:
- Development of a Chronic Kidney Disease Model in C57BL/6 Mice with Relevance to Human PathologyNephron Extra, 2013
- Hepatitis B viral X protein alters the biological features and expressions of DNA repair enzymes in LO2 cellsLiver International, 2010
- Synthesis and Biological Evaluation of Coumarin-Based Inhibitors of NAD(P)H: Quinone Oxidoreductase-1 (NQO1)Journal of Medicinal Chemistry, 2009
- Three Patterns of Cytochrome P450 Gene Expression during Liver Maturation in MiceDrug Metabolism and Disposition, 2009
- A novel cell-permeable antioxidant peptide decreases renal tubular apoptosis and damage in unilateral ureteral obstructionAmerican Journal of Physiology-Renal Physiology, 2008
- The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesisNature Reviews Cancer, 2006
- Human cytosolic enzymes involved in the metabolic activation of carcinogenic aristolochic acid: evidence for reductive activation by human NAD(P)H:quinone oxidoreductaseCarcinogenesis, 2003
- Dicoumarol toxicity in cattle associated with ingestion of silage containing sweet vernal grass (Anthoxanthum odoratum)Australian Veterinary Journal, 2002
- THE EFFECT OF DICUMAROL ON PROTHROMBIN TIME IN RATS AND ITS RELATION TO VITAMIN K CONTENT OF LIVERCanadian Journal of Physiology and Pharmacology, 1965
- Observation on the Mechanism of Action of DicoumarolScience, 1948